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Abstract
Background: Mechanisms underlying alleviation of neuropathic pain by repetitive transcranial magnetic stimulation (rTMS) of
primary motor cortex (M1) and right secondary somatosensory cortex (S2) are only partly known. Patients with chronic neuropathic
pain often have comorbidities like depression and sleep problems. Through functional connectivity, rTMS of M1 and S2 may activate
dorsolateral prefrontal cortex, the target for treating depression with rTMS. Thus, the analgesic effect of rTMS could be mediated
indirectly via improvement of psychiatric comorbidities or sleep. We examined whether rTMS has an independent analgesic effect or
whether its clinical beneﬁts depend on effects on mood or sleep. We also evaluated if comorbid psychiatric or sleep disorders predict
the treatment outcome.
Methods: Sixteen patients with chronic drug-resistant neuropathic orofacial pain participated in this randomized controlled
crossover rTMS study. Patients’ psychiatric history was evaluated by a specialist in psychiatry. Intensity and interference of pain,
mood, and the quality of sleep and life were evaluated at baseline and after 2 active (primary somatosensory cortex [S1]/M1 and S2)
and placebo rTMS treatments. A logistic regression analysis was done to investigate predictors of treatment outcome.
Results: The analgesic effect of the right S2 stimulation was not associated with improvement of psychiatric conditions or sleep,
whereas S1/M1 stimulation improved sleep without signiﬁcant analgesic effect (P=0.013–0.046 in sleep scores). Psychiatric and
sleep disorders were more common in patients than in the general population (P=0.000–0.001 in sleep scores), but these
comorbidities did not predict the rTMS treatment outcome.
Conclusion:We conclude that rTMS to the right S2 does not exert its beneﬁcial analgesic effects in chronic neuropathic orofacial
pain via indirect improvement of comorbid psychiatric or sleep disorders.
Abbreviations: BMI = body mass index, BMS = burning mouth syndrome, BNSQ = Basic Nordic Sleep Questionnaire,
BPI = Brief Pain Inventory, DLPFC = dorsolateral prefrontal cortex, M1 = primary motor cortex, NRS = numerical rating scale,
rTMS = repetitive transcranial magnetic stimulation, S1 = primary somatosensory cortex, S2 = secondary somatosensory cortex,
SCID-I = structured clinical interview for axis I disorders. The MOS Sleep Scale scores: BDI = Beck Depression Inventory,
NePIQoL = Neuropathic Pain Impact on Quality-of-Life, QS = quantity of sleep, SA = sleep adequacy, SLD = sleep disturbance,
SNR = snoring, SOB = awakening with short of breath or a headache, SS = daytime somnolence.
Keywords: neuropathic orofacial pain, psychiatric disorders, repetitive transcranial magnetic stimulation, secondary
somatosensory cortex, sleep disorders[1–7]1. Introduction
Repetitive transcranialmagnetic stimulation (rTMS) targeting either
the primarymotor cortex (M1) or the dorsolateral prefrontal cortex
(DLPFC) has been shown to have an analgesic effect on neuropathicEditor: Michele Fornaro.
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1pain. When targeted to the DLPFC, rTMS has also been shown
effective in treating depression.[7,8] In the ﬁrst part of this study, we
discovered that rTMS given to the right secondary somatosensory
cortex (S2) at the posterior edge of the operculoinsular cortex; the Finnish Medical Foundation, Helsinki, Finland; the Sigrid Jusélius Foundation,
ent of Psychiatry, Turku University Hospital, University of Turku, Turku,
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served.
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proposed it to be a new potential treatment target.[9] In line, S2
stimulation has previously been shown to have analgesic properties
also in healthy subjects.[10] Knowing that there are tight functional
connections between the M1 and prefrontal cortex,[11–16] as well as
between the insular cortex and prefrontal cortex,[17,18] it could be
presumed that similar connections exist between the S2 andDLPFC.
In line with this proposal, studies in nonhuman primates have
revealed reciprocal anatomical connections between the S2 cortex
and DLPFC.[19] Considering these connections, the previously
reported analgesic effect of the right S2 stimulation[9] may be an
indirect effect through improvement of patients’ comorbid psychiat-
ric conditions, which are frequent in neuropathic pain patients.
Pain is a common cause of sleep disruption,[20–22] and disrupted
sleep increases pain sensitivity.[23–28] The relationship between
pain and depression is also bidirectional.[21,29–32] Patients with
treatment-resistant neuropathic pain are particularly susceptible to
concomitant disorders such as sleep problems and
depression.[33–36] These may share some common pathophysio-
logical etiological factors such as low dopaminergic tone.[37–39]
Based on earlier observations of the multidirectional relation-
ship between pain, depression, and sleep, we wanted to study
whether analgesia induced with rTMS depends on the possible
simultaneous improvement of patients’ psychiatric conditions or
sleep disorders. We examined the correlation of the comorbid
psychiatric and sleep disorders with pain symptoms at baseline
and evaluated if the existence of these comorbidities or use of
certain medications could predict the rTMS treatment outcome.
Furthermore, we compared the quality of life (QoL) and sleep
disorders between neuropathic orofacial pain patients and the
general population.
2. Material and methods
2.1. Participants
Twenty patients (mean age 59 years, range 37–74 years, 2 men),
who were previously diagnosed with drug-resistant neuropathic
orofacial pain in Turku University Hospital, participated in thisTable 1
Patients’ demographic and clinical data.
Gender/age in years DG Pain side Duration in years Lifetime
Female/60 AFP Left 10 MDD, GA
Female/64 AFP Right 10 –
Female/55 AFP Right 20 GAD
∗
, S
Female/55 AFP Left 30 MDD
Female/57 BMS Bilateral 5 MDD, Pa
Female/67 BMS Bilateral 20 MDD, Sp
Female/61 BMS Bilateral 2 –
Female/74 BMS Bilateral 7 –
Female/69 BMS Bilateral 10 –
Female/65 TNP Right 15 GAD
∗
, S
Female/57 TNP Bilateral 5 MDD
∗
Female/47 TNP Left 6 MDD, Sp
Female/70 TNP Right 10 SpP, PaD
Female/69 TNP Right 5 –
Male/39 TNP Bilateral 7 GAD
∗
, S
Male/50 TNP Right 5 –
AFP = atypical facial pain, AMI = amitriptyline, BMS= burning mouth syndrome, CHL = chlorediazepoxide
escitalopram, ETO = etoricoxib, FLU = ﬂuvoxamine, GAD = general anxiety disorder, LOR = lorazepam, LT
paracetamol, PGB = pregabalin, SoP = social phobia, SpP = special phobia, tCLO = topical clonazep
∗
Onset after neuropathic pain.
2randomized placebo-controlled study examining the effects of
rTMS on pain.[9] Two patients were later excluded; 1 because of
signiﬁcant brain pathology in magnetic resonance imaging and
one for not fulﬁlling the inclusion criteria of pain intensity at
baseline. Two patients dropped out during the study; 1 because of
major depression and 1 for starting a new treatment during the
study. Finally, 16 patients (mean age 59 years, range 39–74 years,
2 men) accomplished the whole study. Patients’ mean body mass
index (BMI) that may inﬂuence sleep was 27.4 (range 22.1–36.2,
SD 4.1). Seven patients had trigeminal neuropathic pain, 4
atypical facial pain, and 5 burning mouth syndrome (BMS). The
diagnoses were based on clinical examinations performed by an
orofacial pain specialist and a neurologist and on abnormal
ﬁndings in neurophysiological and psychophysical tests (electro-
neuromyography, brainstem reﬂex recordings, contact heat
evoked potentials, and thermal quantitative sensory testing),
performed as described in detail elsewhere.[9,39–41] Despite
normal clinical sensory examination, all patients had abnormal
ﬁndings in thermal quantitative sensory testing and contact heat
evoked potential recordings indicating deﬁcits in the function of
the trigeminal small ﬁber system, some along with large ﬁber
involvement shown in brainstem reﬂexes. The diagnostic criteria
applied in this study comply with the current international
criteria, ICHD 2013 by International Headache Society.[42] The
main inclusion criterion was chronic daily neuropathic orofacial
pain ≥4 in numerical rating scale (NRS) from 0 to 10 (0 for no
pain at all and 10 for the worst imaginable pain). Patients’
average daily pain intensity was 5.7 (SD 1.9) in NRS, and the
mean duration of pain was 10.4 (range 2–30) years. Patients’
demographic and clinical data are shown in detail in Table 1.
None of the patients had contraindications for TMS, such as the
use of a pacemaker or a history of seizures.[43]3. Methods
The study was performed from 2009 to 2011 according to the
Declaration of Helsinki. The present results of rTMS effects on
sleep and QoL measures and predictors of treatment efﬁcacypsychiatric disorders Current psychiatric disorders Daily treatment
D
∗
– ZOL
– –
pP GAD
∗
, SpP –
– AMI+CHL, FLU
TRA, ETO
D – NOR
P MDD, SpP –
– tCLO, ZOP
– tCLO, ZOP
– –
oP SoP LTG
MDD
∗
PGB, NOR, ESC
P SpP PGB, CIT
SpP PAR+COD, LOR
– –
oP – DUL, NOR
– –
, CIT= citalopram, COD = codeine phosphate hemihydrate, DG = diagnosis, DUL = duloxetine, ESC=
G = lamotrigin, MDD = major depressive disorder, NOR = nortriptyline, PaD = panic disorder, PAR =
am, TNP = trigeminal neuropathic pain, TRA = tramadol, ZOL = zolpidem, ZOP = zopiclone.
[10]
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optimal targets for therapeutic, analgesic rTMS. The primary
outcome measure was the change in pain intensity after rTMS
compared to baseline, which has been previously reported.[9]
Here, we describe the secondary outcomes of the effects of rTMS
on psychiatric and sleep disorders, as well as the effects of these
comorbidities on treatment outcome. The study protocol was
approved by the Ethics Committee of the Hospital District of the
Southwest Finland. All participants gave written informed
consent.
The rTMS treatments were given in a single-blind, within-
subject crossover design with 4-week intervals. Each patient
underwent 3 rTMS sessions (2 active and 1 placebo session).
Active rTMS stimulations were given to the facial representation
area of the primary sensorimotor cortex (S1/M1) and the right
secondary somatosensory cortex (S2) in randomized order.
Stimulation targets are shown in Fig. 1. The placebo treatment
was targeted to the same area with same settings as S1/M1
stimulation, but there was a 75-mm plastic block attached to the
coil, which minimized the electric ﬁeld reaching the cortex
negligible. The patients could not see the coil during the treatment
sessions. Stimulation sessions consisted of 1000 (500+500)
pulses with 10Hz frequency. The stimulation was given with an
E-ﬁeld navigated TMS device and a biphasic ﬁgure-8 coil (eXimia
NBS Navigation System and eXimia TMS stimulator, Nextim
Ltd., Helsinki, Finland) in trains of 50 pulses at 10-second
intervals and a 15-minute break after the ﬁrst 500 pulses in order
to cool the coil. The intensity of the stimulation was 90% of the
resting motor threshold determined by single pulse stimulation of
the motor cortex and surface ENMG recording from thenarFigure 1. Repetitive transcranial magnetic stimulation targets. Yellow dot with
arrows marks the secondary somatosensory cortex stimulation target, the red
arrow showing the direction of the main induced electrical ﬁeld vector. The
orange dots mark the S1/M1 stimulation area, that is, the representation area of
the face on the primary somatosensory cortex and primary motor cortex (M1).
Uppermost green dot shows the left hand representation area on theM1 cortex
where the resting motor threshold was measured.
3muscles, as described earlier. The complete rTMS protocol has
been described in detail previously.[9]
Genetic analyses of the functional dopamine receptor DRD2
gene polymorphism (957C>T) and the catechol-O-methyltrans-
ferase Val158Met polymorphism were determined using stan-
dard procedures as described earlier.[39,44]
The psychiatric diagnoses were made by a specialist in
psychiatry with the aid of the structured clinical interview for
axis I disorders (SCID-I).[45] Patients’ current and lifetime
psychiatric diagnoses are shown in Table 1.
Patients’ pain, sleep, mood, and the QoL were evaluated with
diaries and multiple questionnaires at baseline and after the
treatments. Patients kept pain and sleep symptom diaries from 4
weeks before the ﬁrst treatment to 4 weeks after the last
treatment. In the diary, pain and sleep were assessed by using
NRS from 0 to 10. In the case of sleep, 0 indicated the poorest
imaginable quality of sleep and 10 the best possible quality of
sleep. The total amount of sleep was also recorded in hours per
night. The intensity and the interference of pain were measured
with Brief Pain Inventory (BPI)[46] at baseline, 3 to 5 days, and 1
month after the treatments. In the BPI, higher scores are
associated with higher intensity and more interference. Patients’
sleep characteristics during the 3 months preceding the study
were evaluated with the Basic Nordic Sleep Questionnaire
(BNSQ).[47] Sleep was more precisely assessed with Medical
Outcomes Study (MOS) Sleep Measure[48] at baseline and 1
month after each treatment. The MOS Sleep Scale is a 12-item
measure assessing 6 dimensions of sleep: sleep disturbance (SLD),
snoring (SNR), awakening with short of breath or a headache
(SOB), sleep adequacy (SA), daytime somnolence (SS), and
quantity of sleep (QS).[49] The SLD subscore measures the ability
to fall asleep and maintain restful sleep (4 items), the SA subscore
measures the sufﬁciency of sleep (2 items), and the SS subscore
measures daytime drowsiness (3 items).[50] The SNR, SOB, and
QS (in hours) are 1-item subscores. Two sleep problem indices
can be calculated from the subscores. The S6-index contains 6
questions concerning SLD, SA, respiratory impairment, and
somnolence. The S9-index uses 3 more questions to summarize
overall sleep problems. Neither of the indices includes the MOS
Sleep Scale QS question, which is scored as the average hours
slept per night. Other questions and the indices are scored on a 0
to 100 range, where a higher score indicates more sleep-related
disorders. The MOS Sleep Scale has been shown to be useful in
exploring SLDs in patients with neuropathic pain.[51] The health-
related QoL was measured with a validated Finnish version of
RAND-36[52,53] questionnaire at baseline and 1 month after the
treatments. RAND-36 assesses 8 health concepts: physical
functioning, role limitations caused by physical problems, role
limitations caused by emotional problems, social functioning,
emotional wellbeing, energy/fatigue, pain, and general health
perceptions. The RAND scores range from 0 (worst possible
health state) to 100 (best possible health state). The QoL was also
measured with the Neuropathic Pain Impact on Quality-of-Life
(NePIQoL) questionnaire, which is a speciﬁcally designed QoL
measure for neuropathic pain patients.[54] TheNePIQoL contains
42 items in 6 domains: psychological, physical, symptoms,
personal care, relationships, and social/work activity. All
domains have 5-point (1–5) scales with higher scores representing
greater pain-related interference in QoL. Patients’ mood was
evaluated with the widely used and valid Beck Depression
Inventory (BDI),[55] at baseline and weekly during the months
following the treatments. In BDI, higher score implies more severe
symptoms.
Figure 2. Comparison of the MOS Sleep Scale scores between the
neuropathic orofacial pain patients and the US general population. Patients
reported signiﬁcantly worse scores on sleep disturbance, awakening with short
of breath or headache, daytime somnolence, and 9-item sleep problem index
total score compared to the US general population (P values for the
comparisons are shown above the bars for each score). Scores measuring
sleep adequacy and snoring did not differ between the groups.
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The effects of rTMS on pain, QoL, andmood were determined by
repeated measures analysis of variance with time as the within-
subject factor, and diagnosis and genotype as between-subject
factors. P values less than 0.05 were considered statistically
signiﬁcant. In post hoc pairwise comparisons, a correction for
multiple comparisons was done with Bonferroni, and adjusted P
values are reported. Correlations between RAND, NePIQoL,
MOS, BPI, and pain/sleep diary scores were tested using Pearson
correlation coefﬁcients. In addition, the patients’ MOS and
RAND scores at baseline were compared with published
population reference values.[49,52] A logistic regression analysis
was run to ﬁnd out the possible predictive factors inﬂuencing the
treatment effect. Variables used were the baseline pain intensity
and quality of sleep, the existence of social phobia, special
phobia, general anxiety disorder, depression or restless legs, and
use of opioidergic or gabaergic medication that may inﬂuence the
efﬁcacy of rTMS. The dichotomous outcome variable was pain
relief either more or less than 30% from baseline. Power analysis
was done to estimate the minimum sample size required to detect
clinically signiﬁcant 30% decrease in pain intensity. Under the
assumption of 20%dropout rate, with 80% statistical power and
2-sided alpha risk of 0.05, 20 patients had to be enrolled in the
trial. All statistical analyses were carried out by SAS statistical
software package for Windows (SAS Institute Inc., Cary, NC).
4. Results
Baseline sleep disorders (poor quality of sleep and restless legs),
psychiatric disorders (depression, general anxiety disorder, social
phobia, and speciﬁc phobia), or notable medications (opioids and
gabaergic drugs) had no predictive value for the treatment
outcome in any of the stimulation conditions. In the logistic
regression analysis, only the baseline intensity of pain over 5 in
NRS showed a tendency toward some predictive value (P=
0.057) for a positive treatment response following stimulation of
the right S2 cortex.
There were no differences in the BDI scores measuring mood[9]
or in the sleep diary measurements concerning the amount and
the quality of sleep before and after the rTMS treatments.
There was a reduction in the neuropathic pain-speciﬁc
NePIQoL total score after the S2 treatment (P=0.0031) but
no differences in the more general RAND-36 scores after any of
the rTMS treatment sessions, as previously reported.[9] In the
pairwise post hoc comparisons, the MOS Sleep Scale SOB
subscore describing shortness of breath or headache was lower
(P=0.027) after the S2 stimulation than at baseline. The SLD
subscore (P=0.046), and both S6 (P=0.040) and S9 (P=0.013)
index scores describing overall sleep problems, were lower after
the S1/M1 stimulation than at the baseline. However, after
correction for multiple comparisons, only the difference in S9
sleep index score remained signiﬁcant. There were no signiﬁcant
changes in the MOS scores after the placebo treatment. The
speciﬁc diagnoses, genotypes, or medications were not associated
with the treatment responses.
According to the BNSQ questionnaire at baseline, 73% (11/15)
of the patients experienced their sleep being usually poor. More
than half (9/15; 56%) of the patients suffered from SS and early
awakenings more than 3 times a week. A total of 11/16 (69%)
experienced troubles falling asleep more than 3 times a week, and
6/16 (38%) suffered from awakenings more than 3 times per
night. Almost half of the patients (7/16; 43%) used sleepmedicine
more than 3 times a week. A total of 14/16 (88%) had sometimes4snored, but none of them snored more than 3 times per week.
Only 2/16 (13%) had experienced sleep apnea, which in these
cases occurred less than once a week.
Neuropathic orofacial pain patients reported worse scores on 3
of 5 MOS Sleep Scale scores (SLD P=0.000, SOB P=0.000, and
SS P=0.001) compared to the US general population (original
data of the US general population is available at http://gim.med.
ucla.edu/FacultyPages/Hays/surveys/). The 9-item sleep problem
index total score was also poorer in patients than in general
population (P=0.000). Comparison of the score proﬁles between
the patients and healthy population is shown in Fig. 2.
Based on SCID-I interviews, 6 (38%) of the patients had a
present and 10 (63%) a lifetime psychiatric disorder, either
depressive or anxiety disorder or both (Table 1). The lifetime
rates of depressive and anxiety disorders were similar to those
reported earlier for a larger sample of Finnish orofacial pain
patients[37] and higher than in general population.[56] Clinical
and demographic data of the patients are presented in Table 1. All
but 1 of the depressive disorders preceded the neuropathic pain
condition, and the only 1 following the onset of the neuropathic
pain was not related to the pain state. On the contrary, all general
anxiety disorders developed only after the onset of pain and were
closely pain related. The remaining anxiety disorders were
phobias and panic disorders that had begun before the pain.
Especially, speciﬁc phobias were chronic.
TheQoL of the patients at baseline was very variable according
to the RAND scores. In older patients (≥65 years), scores did not
differ from the general population. In the younger age group
(18–64 years), patients were clearly more painful than the general
population, but otherwise, scores differed so much between
individual patients that the results of the statistical analyses
remained nonsigniﬁcant, and no ﬁrm conclusions could be made.
At baseline, higher scores in the BDI (meaning more depressive
symptoms) were associated with lower quality of sleep (R
0.51932, P=0.040), more interference of pain according to BPI
(R 0.70519, P=0.002), and higher total score in the NePIOoL
(meaning lower QoL, R 0.77825, P=0.000). The only RAND
score correlating with BDI was the social functioning, which was
Lindholm et al. Medicine (2016) 95:44 www.md-journal.comlower with higher BDI scores (R 0.62404, P=0.010). There
was an association between QoL and quality of sleep when
measuring the QoL with the NePIQoL questionnaire (better
quality of sleep correlating with better QoL and lower NePIQoL
total score, R 0.74518, P=0.001). The RAND questionnaire
could not reveal this association in this patient group. High
NePIQoL total scores were associated with high BPI interference
of pain scores (R 0.75736, P=0.001), both measuring the
disturbance caused by pain in daily life. High MOS index scores,
indicating more sleep problems, had some association with the
higher interference of pain in the BPI (S6 R 0.50969, P=0.044).
Simple sleep diary scores were well in line with both MOS index
scores: better quality of sleep was associated with lower MOS
index scores (S6 r/R 0.64590, P=0.007 and S9 r/R 0.62431,
P=0.010).5. Discussion
The present results show that the analgesic effect of rTMS given
to the right S2 cortex as previously reported[9] is most likely
due to a direct action on speciﬁc top–down pain modulation
networks rather than a result of an indirect action via
improvement of comorbid psychiatric or sleep disturbances. In
line with this interpretation, the S2 stimulation had no effect on
depressive symptoms, sleep diary measures, or the MOS sleep
scale index scores. Furthermore, comorbidities such as depres-
sion, anxiety disorders, and sleep problems did not predict the
rTMS treatment outcome. The analgesic effect of the S2
stimulation in these neuropathic orofacial pain patients comply
with earlier ﬁndings in healthy subject suggesting that S2
stimulation both impairs the subjective appraisal of painful
stimuli and reduces the perceived pain intensity.[10,57,58]
Although we have not been able to show a signiﬁcant analgesic
effectwith S1/M1 stimulation,[9] this target seemed to have a positive
effect on the MOS sleep scale index scores (S6 and S9) describing
overall sleep problems, and to the sleep disturbance subscore
describing ability to fall asleep and maintain restful sleep. This
discrepancy highlights the importance of precise anatomical
navigation in rTMS treatment, because rather closely located cortical
targets (Fig. 1) maymediate very speciﬁc and distinct effects, and the
beneﬁts reported in pain patientsmay bemediated via different brain
mechanisms. This is in line with the current understanding of the
neurophysiological mechanisms behind rTMS effects.[59] Of special
interest is that the placebo rTMS had no signiﬁcant effects on any of
the many mood, sleep, and QoL variables analyzed in this study,
although placebo effect is usually considered to be approximately
30% in pain trials. The positive effect of the S2 stimulation on the
MOS sleep scale SOB subscore measuring SOB while awakening
could be explained by the stimulation’s analgesic effect on orofacial
pain, ergo, pain in the head. Patients did not report sleep apnea in the
baseline sleep questionnaire, and the mean BMI was normal, so
changes in thisMOS subscore were unlikely due to obstructive sleep
apnea syndrome.
In this small sample of neuropathic orofacial pain patients,
genotypes related to brain dopamine system did not inﬂuence any
of the effects of the rTMS treatment. Nevertheless, higher reported
pain intensity at baseline seemed to have a borderline predictive
value for better treatment response, which is of interest as high
subjective pain scores have previously been shown to associate
with the pain-sensitive 957TT homozygote form of the DRD2
gene.[39] Small sample sizewas indeed a limitation of our study, but
according to power analysis, the sample size was considered
sufﬁcient to detect clinically meaningful changes. Another clear5limitation was the absence of a placebo coil. When asked after the
study was completed, 6 of the 16 patients recognized correctly the
placebo stimulation, 2 because of the muscle contraction during
active rTMS and 4 because of the beneﬁcial effects of the active
treatments. The effects of the previous active stimulation did not
have an impact on the following placebo session.
Sleep disturbances were far more common among chronic
neuropathic orofacial pain patients than in general population,
which is in line with earlier reports on BMS patients[60,61] and
neuropathic pain patients in general.[33,35,36] Sleep disturbances
were associatedwithmore interference caused by pain in daily life
(NePIQoL and BPI), but not with the mere intensity of pain. The
same trend was seen with depressive symptoms that were also
more pronounced in patients reporting more interference of pain
in daily life (NePIQoL and BPI) and poorer quality of sleep,
whereas the intensity of pain was not associated with the
occurrence of depressive symptoms. It has been shown earlier
that a negative cognitive and affective response to pain, so-called
pain catastrophizing, might contribute to sleep disturbance in
chronic pain.[62,63] We did not have questionnaires to measure
pain catastrophizing, but in the NePiQoL questionnaire there
were many questions concerning coping with the pain and the
NePiQoL total score correlated with the sleep disturbance,
whereas pain intensity in the BPI and pain diary did not.
The neuropathic orofacial pain patients had more depressive
and anxiety disorders than the general population. Depressive
disorders mostly preceded the onset of pain, which is in line with
other studies concerning orofacial pain.[37,64,65] In contrast,
general anxiety disorders followed the pain and were closely pain
related. The association between chronic pain and psychiatric
disorders has been considered before,[37,66,67] and in the case of
neuropathic orofacial pain, the shared vulnerability through
hypofunctional brain dopamine activity could be a possible
underlying predisposing factor both to depression and chronic
pain.[39,68–72] This hypothesis is further supported by the fact that
the pain vulnerable DRD2 gene genotype 957TT carriers with
low striatal dopamine content were overrepresented (50% vs
27% in general population) in this study group of neuropathic
orofacial pain patients, as reported earlier.[39] The occurrence of
the anxiety disorder after the onset of pain could also be
explained by the hypofunctional dopamine activity, as it has been
suggested that the personality trait of harm avoidance is
associated with low levels of dopamine in the striatum.[73] The
personality trait of harm avoidance predisposes to worrying and
catastrophizing about the pain and may lead to the onset of a
general anxiety disorder, which in turn is shown to be associated
with low striatal dopamine synthesis capacity.[74] The analgesic
effect of S2 stimulation could therefore depend on the dopamine
release induced change in attentional factors related to coping
with pain, as it has been earlier shown that S2 stimulation
induced an early decrease in discriminative capacity[10,57] and
after a delay, an increase in response criterion.[10] This attitude
change toward disregarding pain stimuli may underlie the clinical
effects of S2 stimulation.6. Conclusion
The rTMS applied to the right S2 cortex does not seem to exert its
beneﬁcial effects via indirect improvement of mood or sleep
disturbances that the orofacial neuropathic pain patients had.
Patients hadmore psychiatric and sleep disorders than the general
population, but these comorbidities did not predict the rTMS
treatment outcome either. There were associations between
[27] Lautenbacher S, Kundermann B, Krieg JC. Sleep deprivation and pain
Lindholm et al. Medicine (2016) 95:44 Medicinebaseline depressive symptoms, sleep, and the interference of pain
supporting the known complex relationship between these
disorders.
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